Cargando…
25. Immunogenicity and Reactogenicity of COVID-19 mRNA Vaccines in Allogeneic Stem Cell Transplant Recipients
BACKGROUND: Allogeneic stem cell transplant (SCT) recipients are at an increased risk of poor outcomes from COVID-19. While the mRNA-1273 (Moderna) and BNT162b2 (Pfizer) COVID-19 mRNA vaccines are highly immunogenic in the general population, the immune response in SCT recipients is poorly understoo...
Autores principales: | Bausk, Bruce P, Sherman, Amy C, Desjardins, Michaël, Izaguirre, Natalie E, Cheng, Chi-An, Powell, Megan, Senussi, Yasmeen, Gilboa, Tal, Krauss, Jonathan H, Dirr, Bonnie, Power, Elyssa, Joyce, Amy, Stewart, Lisa, Ometoruwa, Omolola, Novack, Lewis A, Evans, Bethany, Woods, Tenaizus, Tong, Alexandra, Walt, David, Soiffer, Robert, Ho, Vincent T, Issa, Nicolas C, Baden, Lindsey R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644500/ http://dx.doi.org/10.1093/ofid/ofab466.025 |
Ejemplares similares
-
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
por: Crombie, Jennifer L., et al.
Publicado: (2021) -
586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021) -
36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020) -
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies
por: Sherman, Amy C, et al.
Publicado: (2022) -
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation
por: Sherman, Amy C., et al.
Publicado: (2023)